ALZN: יחס שווי שוק להכנסות Alzamend Neuro, Inc.

The potential of Alzamend Neuro, Inc. (ALZN) is based on insurance fund payouts for dementia therapy. Innovative cellular vaccines and lithium developments confirm the firm's scientific status, although the speculative pipeline is already priced in. The GURU.Markets terminal displays the company's P/S chart, where the P/S price action reflects the business value relative to revenue, and the current level is .

Institutional capital maintains a cautious valuation of Alzamend Neuro, Inc. (ALZN), as the high emotional attachment of retail investors to the fight against Alzheimer's disease often inflates share prices relative to actual earnings. By analyzing the P/S ratio dynamics, an investor can observe the relationship between market capitalization and annual revenue, which helps determine the premium paid for the future success of clinical trials and assess the fundamental stability of the asset.